Has Janki Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,854 in general payments to Janki Shah, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Janki Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Janki Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Janki Shah, MD

Cardiovascular Disease · Santa Monica, CANPI 1497826325

Payments from drug & device makers

$25,854in general payments, 2019–2025

Across 9 payments — averaging $2872.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$26K
Heartflow, Inc.$142
Abbott$98
Baxter Healthcare$33

What the payments were for

Consulting fees$25,58299%
Food & beverage$2391%
Other$330%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	6	$25,582
Heartflow, Inc.	1	$142
Abbott	1	$98
Baxter Healthcare	1	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Repatha$25,582
FFRct$142

How this compares

$25,854 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$587,257

Medicare patients

1,779

Services billed

6,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Repatha SureclickEvolocumab	257	$325,332
XareltoRivaroxaban	213	$268,342
EliquisApixaban	175	$241,916
Praluent PenAlirocumab	67	$68,685
EntrestoSacubitril/Valsartan	19	$34,327
FarxigaDapagliflozin Propanediol	23	$33,431
JardianceEmpagliflozin	25	$27,913
VascepaIcosapent Ethyl	24	$23,165
Rosuvastatin Calcium	835	$16,212
Ezetimibe	291	$12,298
DiovanValsartan	18	$10,992
Metoprolol Succinate	565	$10,278
Atorvastatin Calcium	718	$8,394
Amlodipine Besylate	683	$6,383
Losartan Potassium	438	$5,600

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Santa Monica

Ted LoveHillsborough$102.8M
Matthew BudoffTorrance$11.3M
Lori DanielsSan Diego$10.2M
Paul KurthSanta Barbara$6.1M
Michael BlumSan Francisco$5.5M
Tony ChouSan Francisco$5.2M
Jason RogersSacramento$5.1M
Yu-Ping WangStanford$3.8M
Yogesh PaliwalPomona$3.3M
Farhad RafiiWest Hills$3.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →